ASMB
ASSEMBLY BIOSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$19.87
−0.25%0
Insider buys (3m)
8
Insider sells (3m)
-$237.6K
Net value (3m)
-25.4%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Nov 3, 2026 | Bjorkquist Jeanette M · officer: PFO and PAO | Sale | 718 | $20 |
| Nov 3, 2026 | Okazaki Jason A · director, officer: CEO and President | Sale | 69 | $20 |
| Nov 3, 2026 | Okazaki Jason A · director, officer: CEO and President | Sale | 6,133 | $20 |
| Nov 3, 2026 | Okazaki Jason A · director, officer: CEO and President | A-Award | 38,380 | $0.00 |
| Nov 3, 2026 | Gaggar Anuj · officer: Chief Medical Officer | Sale | 29 | $20 |
| Nov 3, 2026 | Gaggar Anuj · officer: Chief Medical Officer | Sale | 2,564 | $20 |
| Nov 3, 2026 | Gaggar Anuj · officer: Chief Medical Officer | A-Award | 13,705 | $0.00 |
| Nov 3, 2026 | Delaney William E IV · officer: Chief Scientific Officer | A-Award | 13,705 | $0.00 |
| Nov 3, 2026 | White Nicole S · officer: Chief Manufacturing Officer | Sale | 29 | $20 |
| Nov 3, 2026 | White Nicole S · officer: Chief Manufacturing Officer | Sale | 2,564 | $20 |
| Nov 3, 2026 | White Nicole S · officer: Chief Manufacturing Officer | A-Award | 13,705 | $0.00 |
| Nov 3, 2026 | Bjorkquist Jeanette M · officer: PFO and PAO | A-Award | 3,840 | $0.00 |
| Nov 3, 2026 | Bjorkquist Jeanette M · officer: PFO and PAO | Sale | 9 | $20 |
| Jun 18, 2026 | Bjorkquist Jeanette M · officer: PFO and PAO | Sale | 29 | $23 |
| Jun 5, 2026 | Okazaki Jason A · director, officer: CEO and President | A-Award | 50,750 | $0.00 |
| Jun 5, 2026 | Bjorkquist Jeanette M · officer: PFO and PAO | A-Award | 3,500 | $0.00 |
| Jun 5, 2026 | ALTIG ANTHONY E · director | A-Award | 8,000 | $24 |
| Jun 5, 2026 | Consylman Gina · director | A-Award | 8,000 | $24 |
| Jun 5, 2026 | Houghton Michael · director | A-Award | 8,000 | $24 |
| Jun 5, 2026 | Johnson-Pratt Lisa · director | A-Award | 8,000 | $24 |
| Jun 5, 2026 | Mahony Susan · director | A-Award | 8,000 | $24 |
| Jun 5, 2026 | McHutchison John G · director | A-Award | 8,000 | $24 |
| Jun 5, 2026 | White Nicole S · officer: Chief Manufacturing Officer | A-Award | 14,000 | $0.00 |
| Jun 5, 2026 | Gaggar Anuj · officer: Chief Medical Officer | A-Award | 14,000 | $0.00 |
| Jun 5, 2026 | Delaney William E IV · officer: Chief Scientific Officer | A-Award | 14,000 | $0.00 |
| May 27, 2026 | GILEAD SCIENCES, INC. · 10 percent owner | A-Award | 471,698 | $27 |
| Mar 31, 2026 | Delaney William E IV · officer: Chief Scientific Officer | A-Award | 26,000 | $0.00 |
| Mar 31, 2026 | Okazaki Jason A · director, officer: CEO and President | A-Award | 94,250 | $0.00 |
| Mar 31, 2026 | White Nicole S · officer: Chief Manufacturing Officer | Sale | 9 | $27 |
| Mar 31, 2026 | Bjorkquist Jeanette M · officer: PFO and PAO | A-Award | 6,500 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 52Increased 60Reduced 39Sold out 14
| Filer | Action | Shares | Filed |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Increased | 4,977,089 | Aug 3, 2026 |
| GILEAD SCIENCES, INC. | Unchanged | 4,505,391 | May 8, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 1,604,590 | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | Increased | 1,553,748 | Aug 14, 2026 |
| Commodore Capital LP | Increased | 1,415,000 | Aug 14, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Unchanged | 1,227,590 | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 1,020,410 | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 1,020,410 | Aug 14, 2026 |
| COMMODORE CAPITAL LP | Unchanged | 1,000,000 | May 15, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 849,309 | May 18, 2026 |
| Jupiter Topco LLC | New Position | 849,309 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 766,819 | Aug 7, 2026 |
| Parkman Healthcare Partners LLC | Increased | 721,181 | Aug 14, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Unchanged | 665,251 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 558,942 | Aug 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Nov 3, 2026